Emerging therapies for the treatment of neovascular age related macular degeneration

Seminars in Ophthalmology

Volumn 26, Issue 3, 2011, Pages 149-155

  Yuan, Alex ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

angiogenesis; macular degeneration; vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; AG 013958; AL 39324; ATG 003; BEVACIZUMAB; DACLIZUMAB; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONEP; JSM 6437; KH 902; MATRIX METALLOPROTEINASE; MECAMYLAMINE; MONOCLONAL ANTIBODY; PALOMID 529; PAZOPANIB; PEGAPTANIB; PF 04523655; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RANIBIZUMAB; RAPAMYCIN; SONEPCIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALINAB; VOLOCIXIMAB;

ANGIOGENESIS; AUTOPHOSPHORYLATION; BLOOD VESSEL PERMEABILITY; CELL GROWTH; CELL PROLIFERATION; CHEMOTAXIS; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; EXUDATIVE MACULAR DEGENERATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; REVIEW; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; HUMANS; WET MACULAR DEGENERATION;

EID: 79957615782     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2011.570846     Document Type: Review

References (37)

1. Friedman DS, O'Colmain BJ, Munoz B et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004; 122(4):564-572. (Pubitemid 38456293)
2. Congdon N, O'Colmain B, Klaver CC et al. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 2004; 122(4):477-485. (Pubitemid 38456282)
3. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006; 355(14):1419-1431. (Pubitemid 44511557)
4. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006; 355(14):1432-1444. (Pubitemid 44511558)
5. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 2004; 25(4):581-611. (Pubitemid 39099316)
6. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer. Cell. 2007; 12(1):9-22. (Pubitemid 47001784)
7. Nussenblatt RB, Byrnes G, Sen N et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010; 30(10):1579-1587.
8. Brugarolas J, Lei K, Hurley RL et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004; 18(23):2893-2904. (Pubitemid 39602308)
9. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin. Investig. Drugs 2007; 16(1):83-107. (Pubitemid 44964169)
10. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer. 2003; 3(6):401-410. (Pubitemid 37328844)
11. Holekamp NM, Bouck N, Volpert O. Pigment epitheliumderived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am. J. Ophthalmol. 2002; 134(2):220-227. (Pubitemid 34831826)
12. Mori K, Duh E, Gehlbach P et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J. Cell. Physiol. 2001; 188(2):253-263. (Pubitemid 32622916)
13. Mori K, Gehlbach P, Yamamoto S et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2002; 43(6):1994-2000. (Pubitemid 34587052)
14. Campochiaro PA, Nguyen QD, Shah SM et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum. Gene Ther. 2006; 17(2):167-176. (Pubitemid 43262032)
15. Lee MJ, Van Brocklyn JR, Thangada S et al. Sphingosine-1- phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998; 279(5356):1552-1555. (Pubitemid 28217081)
16. Xie B, Shen J, Dong A et al. Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J. Cell. Physiol. 2009; 218(1):192-198.
17. Heeschen C, Weis M, Aicher A et al. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J. Clin. Invest. 2002; 110(4):527-536. (Pubitemid 34919707)
18. Kiuchi K, Matsuoka M, Wu JC et al. Mecamylamine suppresses basal and nicotine-stimulated choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2008; 49(4):1705-1711.
19. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264(5158):569-571.
20. Kim S, Bell K, Mousa SA et al. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am. J. Pathol. 2000; 156(4): 1345-1362. (Pubitemid 30660012)
21. Parsons-Wingerter P, Kasman IM, Norberg S et al. Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am. J. Pathol. 2005; 167(1):193-211. (Pubitemid 40884781)
22. Wilson SH, Ljubimov AV, Morla AO et al. Fibronectin fragments promote human retinal endothelial cell adhesion and proliferation and ERK activation through alpha5beta1 integrin and PI 3-kinase. Invest. Ophthalmol. Vis. Sci. 2003; 44(4):1704-1715. (Pubitemid 36378601)
23. Yang JT, Rayburn H, Hynes RO Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 1993; 119(4):1093-1105. (Pubitemid 23358579)
24. Fassler R, Meyer M. Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev. 1995; 9(15):1896-1908.
25. George EL, Georges-Labouesse EN, Patel-King RS et al. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993; 119(4):1079-1091. (Pubitemid 23358578)
26. Ramakrishnan V, Bhaskar V, Law DA et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel antiangiogenic agent. J. Exp. Ther. Oncol. 2006; 5(4):273-286. (Pubitemid 44497002)
27. Zahn G, Vossmeyer D, Stragies R et al. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch. Ophthalmol. 2009; 127(10):1329-1335.
28. Zahn G, Volk K, Lewis GP et al. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. Invest. Ophthalmol. Vis. Sci. 2010; 51(2):1028-1035.
29. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125(9):1591-1598. (Pubitemid 28256727)
30. Gee MS, Procopio WN, Makonnen S et al. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am. J. Pathol. 2003; 162(1):183-193. (Pubitemid 36042000)
31. Lindahl P, Johansson BR, Leveen P et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277(5323):242-245. (Pubitemid 27446080)
32. Jo N, Mailhos C, Ju M et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of antivascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am. J. Pathol. 2006; 168(6):2036-2053. (Pubitemid 43825322)
33. Dark GG, Hill SA, Prise VE et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997; 57(10):1829-1834. (Pubitemid 27209705)
34. Nambu H, Nambu R, Melia M et al. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2003; 44(8):3650-3655. (Pubitemid 36909807)
35. Williams PB, Lattanzio FA, Jr., Grevem CM et al. OC-10X, a novel tubulin inhibitor, inhibits neovascularization in a nonhuman primate model of AMD. ARVO 2010.
36. Anderson DH, Radeke MJ, Gallo NB et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin. Eye Res. 2010; 29(2):95-112.
37. Zarbin MA, Rosenfeld PJ. Pathway-based therapies for agerelated macular degeneration: An integrated survey of emerging treatment alternatives. Retina 2010; 30(9):1350-1367.